Infertility Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Infertility Drugs Market Report is Segmented by Drug Class (Gonadotrophins, Aromatase Inhibitors, Selective Estrogen Receptor Modulators [SERMs], Biguanides, and Other Drug Classes), End User (Male and Female), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Other Distribution Channels), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers the Value (USD) for the Above Segments.

Infertility Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Infertility Drugs Market Size

Infertility Drugs Market Summary
Study Period 2019 - 2030
Market Size (2025) USD 4.22 Billion
Market Size (2030) USD 5.68 Billion
CAGR (2025 - 2030) 6.12 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Infertility Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Infertility Drugs Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Infertility Drugs Market Analysis

The Infertility Drugs Market size is estimated at USD 4.22 billion in 2025, and is expected to reach USD 5.68 billion by 2030, at a CAGR of 6.12% during the forecast period (2025-2030).

Factors such as the increasing global prevalence of stress and lifestyle-related disorders among men and women, the rise in healthcare awareness, and the increasingly aging female population are expected to boost the Infertility Treatment Market growth.

Infertility continues to pose a global health challenge owing to demographic shifts and continuous lifestyle problems, including obesity, anxiety, and stress, that cause delayed childbearing. For instance, according to the data published by Alcoholic Beverage Consumption Statistics in February 2023, about 63% of adults in the United States aged 18 years or older drank alcohol in 2022, impacting Infertility Rates by Country. Furthermore, according to the data published by the Australian Institutes of Health and Welfare in February 2024, about 6.6 million people consumed alcohol at risky levels during 2022-2023, the same as the number of people in the previous year. Thus, high consumption of alcohol leads to an increase in infertility rates among individuals, which is expected to boost the Infertility Drugs Market growth over the forecast period.

As per the data published in Alcohol Consumption Statistics United Kingdom in February 2023, 12.5% of adults in the United Kingdom reported being teetotal, compared to the country's adult alcohol consumption rate of 71.2% who drank at least once a week. Thus, the high consumption of alcohol affects fertility in males and females. This, in turn, is anticipated to fuel the demand for infertility drugs, thereby propelling the Infertility Therapies Market over the forecast period.

The prevalence of poor fertility among the population is also the key factor driving Infertility Market growth. For instance, according to an article published by the National Library of Medicine in July 2022, about 15% of American couples and at least 180 million other people worldwide were diagnosed with infertility. It is estimated that 9% of Australian men and 8% to 12% of Eastern European men experience infertility issues. Thus, the high prevalence of infertility among the male population is expected to increase the demand for effective drugs, thereby propelling the Infertility Solutions Market.

Furthermore, governments and organizations are increasingly focusing on launching various campaigns to raise awareness regarding fertility care and treatment. For instance, in July 2022, Oasis Fertility launched the Infertility Knows No Gender campaign to commemorate World IVF Day. IVF offers a ray of hope to millions of couples struggling with infertility. In April 2022, Walgreens launched a fertility awareness campaign in support of National Infertility Awareness Week. Such initiatives are anticipated to raise the demand for IVF treatment, fueling Fertility Treatments Market growth over the forecast period.

Therefore, the market studied is expected to grow over the forecast period due to the factors above, such as the high prevalence of poor fertility, increasing sedentary lifestyle, and a growing number of awareness campaigns. However, the stringent regulatory framework for drug approval is expected to impede the growth of the Infertility Drugs Market over the forecast period.

Infertility Drugs Industry Overview

The Infertility Drugs Market is semi-consolidated and consists of several major Fertility Pharmaceutical Companies. The key players are also involved in various strategic alliances such as acquisitions, collaborations, and launching advanced products and research studies to secure their position in the global market. Some of the key companies in the market are Ferring Pharmaceuticals Inc., Pfizer Inc., Merck KGaA, Bayer AG, Takeda Pharmaceutical Company Limited, and Novartis AG.

Infertility Drugs Market Leaders

  1. Ferring Pharmaceuticals Inc

  2. Pfizer Inc.

  3. Merck KGaA

  4. Novartis International AG

  5. Bayer AG

  6. *Disclaimer: Major Players sorted in no particular order
Infertility Drugs Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Infertility Drugs Market News

  • February 2024: Lupin Limited launched the Ganirelix Acetate Injection, 250 mcg/0.5 ml, single-dose prefilled syringe for infertility treatment. This launch followed the approval granted by the US Food and Drug Administration.
  • February 2023: Russia started producing recombinant follicle-stimulating hormone in-house, including two other IVF drugs. In addition, the company plans to produce human chorionic gonadotropin hormone using biotechnology to overcome the shortage of raw materials.

Infertility Drugs Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumption and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Global Prevalence of Stress and Lifestyle Disorders among Men and Women
    • 4.2.2 Rise in Healthcare Awareness along with Increasing Aging Female Population
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Framework that Delays the Approval of Products
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Drug Class
    • 5.1.1 Gonadotrophins
    • 5.1.2 Aromatase Inhibitors
    • 5.1.3 Selective Estrogen Receptor Modulators (SERMs)
    • 5.1.4 Biguanides
    • 5.1.5 Other Drug Classes
  • 5.2 By End User
    • 5.2.1 Male
    • 5.2.2 Female
  • 5.3 By Distribution Channel
    • 5.3.1 Hospital Pharmacies
    • 5.3.2 Retail Pharmacies
    • 5.3.3 Other Distribution Channels
  • 5.4 By Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Ferring Pharmaceuticals Inc.
    • 6.1.3 Merck KGaA
    • 6.1.4 Pfizer Inc.
    • 6.1.5 Novartis International AG
    • 6.1.6 Bayer AG
    • 6.1.7 Theramex
    • 6.1.8 Mankind Pharma
    • 6.1.9 Teva Pharmaceticals Industries
    • 6.1.10 Livzon
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Infertility Drugs Industry Segmentation

As per the scope of the report, infertility is the inability of a woman to become pregnant after one year (or longer) of unprotected sex. The fertility rate decreases with age 35 or above in both men and women. Medicines that regulate or stimulate ovulation are known as fertility drugs. Fertility drugs are the main treatment for infertile women due to ovulation disorders. Fertility drugs generally work with natural hormones, such as follicle-stimulating hormone (FSH) and luteinizing hormone (LH), to trigger ovulation.

The infertility drugs market is segmented by drug class, end user, distribution channel, and geography. By drug class, the market is segmented as gonadotrophins, aromatase inhibitors, selective estrogen receptor modulators (SERMs), biguanides, and other drug classes. By end user, the market is segmented as male and female. By distribution channel, the market is segmented as hospital pharmacies, retail pharmacies, and other distribution channels. By geography, the market is segmented as North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (USD) for the above segments.

By Drug Class Gonadotrophins
Aromatase Inhibitors
Selective Estrogen Receptor Modulators (SERMs)
Biguanides
Other Drug Classes
By End User Male
Female
By Distribution Channel Hospital Pharmacies
Retail Pharmacies
Other Distribution Channels
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Infertility Drugs Market Research FAQs

How big is the Infertility Drugs Market?

The Infertility Drugs Market size is expected to reach USD 4.22 billion in 2025 and grow at a CAGR of 6.12% to reach USD 5.68 billion by 2030.

What is the current Infertility Drugs Market size?

In 2025, the Infertility Drugs Market size is expected to reach USD 4.22 billion.

Who are the key players in Infertility Drugs Market?

Ferring Pharmaceuticals Inc, Pfizer Inc., Merck KGaA, Novartis International AG and Bayer AG are the major companies operating in the Infertility Drugs Market.

Which is the fastest growing region in Infertility Drugs Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Infertility Drugs Market?

In 2025, the North America accounts for the largest market share in Infertility Drugs Market.

What years does this Infertility Drugs Market cover, and what was the market size in 2024?

In 2024, the Infertility Drugs Market size was estimated at USD 3.96 billion. The report covers the Infertility Drugs Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Infertility Drugs Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Global Infertility Drugs Industry Report

Statistics for the 2025 Infertility Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Infertility Drugs analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.